Pelthos Therapeutics (PTHS) Financial Statements & Analysis

Pelthos Therapeutics (PTHS) Income Statement

Pelthos Therapeutics reported revenue of $16.80M in fiscal 2025 (fiscal year ended Dec 31, 2025). Pelthos Therapeutics posted a net loss of $43.32M, compared with a net loss of $7.96M a year earlier. Gross margin was 44.2% and operating margin -193.1%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $15.60M.

Pelthos Therapeutics Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Pelthos Therapeutics Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	16.80	0.00	0.00	0.00	0.00	0.20
Cost of Revenue	9.37	0.00	0.00	0.00	0.21	0.14
Gross Profit	7.43	0.00	0.00	0.00	-0.21	0.06
Operating Expenses
Research & Development	1.23	1.18	2.58	0.39	0.21	0.14
Selling, General & Administrative	37.08	6.39	4.28	1.93	0.63	1.42
Operating Expenses	39.86	7.57	6.86	2.32	0.84	1.55
Operating Income	-32.43	-7.57	-6.86	-2.32	-0.84	-1.35
Other Income/Expense
Interest Income	0.01	0.40	0.00	0.00	0.00	0.00
Interest Expense	3.01	0.79	-0.52	0.14	0.00	0.00
Other Income/Expense	-15.27	0.40	-0.52	-0.14	0.24	0.69
Income
Income Before Tax	-50.71	-7.96	-7.38	-2.46	-0.60	-0.66
Income Tax Expense	-7.39	0.00	0.00	0.00	-0.84	-1.35
Net Income	-43.32	-7.96	-7.38	-2.46	-0.60	-0.66
Net Income - Continuous Operations	-43.32	-7.96	-7.38	-2.46	-0.60	-0.66
Net Income - Discontinued Operations	-	-	-	-	-	-
EBITDA	-45.41	-7.17	-6.86	-2.32	0.00	0.00
EBIT	-47.69	-7.17	-6.86	-2.32	-0.84	-1.35
Depreciation & Amortization	1.56	0.00	0.00	0.00	0.84	1.35
Earnings Per Share
Basic EPS	-23.00	-14.00	-58.00	-3.00	-	-
Diluted EPS	-23.00	-14.00	-58.00	-3.00	-	-
Basic Shares Outstanding	1.88	0.56	0.13	0.93	5.77	5.77
Diluted Shares Outstanding	1.88	0.56	0.13	0.93	5.77	5.77

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Pelthos Therapeutics Financial Statements

What was Pelthos Therapeutics's revenue in fiscal 2025?

Pelthos Therapeutics reported revenue of $16.80M in fiscal 2025 (fiscal year ended Dec 31, 2025).

Is Pelthos Therapeutics profitable?

No. Pelthos Therapeutics reported a net loss of $43.32M in fiscal 2025. In fiscal 2024 it lost $7.96M.

What is Pelthos Therapeutics's operating margin?

Pelthos Therapeutics's operating income was −$32.43M on revenue of $16.80M in fiscal 2025, an operating margin of -193.1%.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition